Sage's depression drug succeeds in mid-stage study

(Reuters) – Sage Therapeutics Inc said on Thursday its drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

The 89-patient study testing the drug, SAGE-217, showed statistically significant reduction of depression symptoms, compared to a placebo.

Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta

Our Standards:The Thomson Reuters Trust Principles.

Leave a Reply

Your email address will not be published. Required fields are marked *